These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9148359)

  • 41. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of unfractionated heparin and low molecular weight heparins in pregnancy.
    Casele HL
    Clin Obstet Gynecol; 2006 Dec; 49(4):895-905. PubMed ID: 17082684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The pharmacological characteristics and clinical use of low-molecular-weight heparins].
    Golota VIa; Gamisoniia MSh
    Lik Sprava; 1998 Dec; (8):15-7. PubMed ID: 10204338
    [No Abstract]   [Full Text] [Related]  

  • 44. [Prevention of thromboembolism with low-molecular weight heparin in pregnancy].
    Harenberg J; Leber G; Zimmermann R; Schmidt W
    Geburtshilfe Frauenheilkd; 1987 Jan; 47(1):15-8. PubMed ID: 3569823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An objective evaluation of the clinical potential of low molecular weight heparins in the prevention of thromboembolism.
    Haas S; Blümel G
    Semin Thromb Hemost; 1989 Oct; 15(4):424-34. PubMed ID: 2554503
    [No Abstract]   [Full Text] [Related]  

  • 46. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 47. Future of anticoagulant therapy.
    Harenberg J; Wehling M
    Cardiovasc Ther; 2011 Oct; 29(5):291-300. PubMed ID: 20626401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Non controlled prospective study of the efficacy and tolerance of a low molecular weight heparin].
    Wattrisse G; Lecoutre D; Groux-Pante C
    J Mal Vasc; 1991; 16(4):367-71. PubMed ID: 1665169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secondary prophylaxis of venous thromboembolism: rational use of oral anticoagulants.
    Piovella F; Siragusa S; Barone M; Beltrametti C; Carbone S; Vicentini L; Ascari E
    Haematologica; 1995; 80(2 Suppl):87-91. PubMed ID: 7543072
    [No Abstract]   [Full Text] [Related]  

  • 50. Current use of low molecular weight heparins.
    Donayre CE
    Semin Vasc Surg; 1996 Dec; 9(4):362-71. PubMed ID: 8958613
    [No Abstract]   [Full Text] [Related]  

  • 51. [Prevention of postoperative thromboembolic complications (a review of the literature)].
    Pavlovskiĭ DP; Baluda VP; Sushkevich GN
    Khirurgiia (Mosk); 1977 May; (5):124-30. PubMed ID: 325273
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of anticoagulants on cancer: heparins.
    Pineo GF; Hull RD
    Cancer Treat Res; 2009; 148():259-75. PubMed ID: 19377929
    [No Abstract]   [Full Text] [Related]  

  • 53. Low molecular weight heparins and external pneumatic compression as options for venous thromboembolism prophylaxis: a surgeon's perspective.
    Caprini JA; Arcelus JI; Traverso CI; Hasty JH
    Semin Thromb Hemost; 1991 Oct; 17(4):356-66. PubMed ID: 1666456
    [No Abstract]   [Full Text] [Related]  

  • 54. [Low-molecular weight heparins in post-surgical recovery].
    Doutremepuich C; Anne MC; Fernandez G; Pereira F; de Seze O; Doutremepuich F
    Ann Biol Clin (Paris); 1988; 46(3):190-4. PubMed ID: 2841894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy.
    McColl MD; Greer IA
    Curr Opin Pulm Med; 2004 Sep; 10(5):371-5. PubMed ID: 15316434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Use of low molecular weight heparins].
    Llau JV; Hoyas L; Ezpeleta J; García-Polit J
    Rev Esp Anestesiol Reanim; 1997 Feb; 44(2):88-9. PubMed ID: 9148365
    [No Abstract]   [Full Text] [Related]  

  • 57. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
    Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
    Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Managing the risk of venous thromboembolism in orthopedics: concluding remarks.
    Haas S
    Orthopedics; 1997 Feb; 20 Suppl():26-7. PubMed ID: 9048405
    [No Abstract]   [Full Text] [Related]  

  • 59. [The role of clivarin in the preventive therapy of thromboembolism].
    Mircea N; Jianu E; Boacă R; Burcoş T; Jitea N; Greere M; Leoveanu A; Angelescu N
    Chirurgia (Bucur); 1996; 45(6):337-41. PubMed ID: 9091088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anti-Xa activity during administration of low-molecular weight heparin in the prevention of postoperative thromboembolic complications].
    Gürlich R; Salaj P; Hrachovinová I
    Rozhl Chir; 1999 Dec; 78(12):618-21. PubMed ID: 10746083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.